Patent ID: 6524347
Filing Date: 2003-02-25
Classification: A61P,C07D

Abstract:
A method of inhibiting abnormal cell proliferation, differentiation or platelet-derived growth factor (PDGF) or p56lck tyrosine kinase receptor mediator release in a patient having a disease characterized thereby, said method comprising administering to said patient a therapeutically effect amount of a pharmaceutical composition comprising a pharmaceutically accessible carrier and a compound having the formula: wherein R1a is selected from the group consisting of optionally substituted one to ten carbon atom alkyl, hydroxy, acyloxy, optionally substituted one to ten carbon atom alkoxy, optionally substituted three to seven carbon atom cycloalkyloxy, optionally substituted four to seven ring member oxaheterocyclyloxy, optionally substituted four to seven ring member heterocyclycarbonyloxy and halo;R1b is selected from the group consisting of hydrogen, optionally substituted one to ten carbon atom alkyl, hydroxy, acyloxy, optionally substituted one to ten carbon atom alkoxy, optionally substituted three to seven carbon atom cycloalkyloxy, optionally substituted four to seven ring member oxaheterocyclyloxy, optionally substituted four to seven ring member heterocyclycarbonyloxy and halo; R1c is selected from the group consisting of hydrogen, optionally substituted one to ten carbon atom alkyl, optionally substituted phenyl, optionally substituted naphthyl, optionally substituted five to ten ring member heteroaryl, hydroxy, acyloxy, optionally substituted one to ten carbon atom alkoxy, optionally substituted three to seven carbon atom cycloalkyloxy, optionally substituted four to seven ring member heterocyclyloxy, optionally substituted phenyloxy, optionally substituted naphthyloxy, optionally substituted five to ten ring member heteroaryloxy, optionally substituted four to seven ring member heterocyclylcarbonyloxy, halo, cyano, R5R6N- and acylR5N-; R3 is selected from the group consisting of hydrogen, ortho-fluoro, para-fluoro, meta-lower-alkyl, lower alkloxy, bromo, iodo and carbamoyl; R4 is hydrogen or lower alkyl; R5 and R6 are independently hydrogen or alkyl; Za is N; and Zb is NH or O, or an N-oxide thereof, hydrate thereof, solvate thereof, prodrug thereof, or pharmaceutically acceptable salt thereof, provided that R1a and R1b are not both optionally substituted alkyl.